Topotecan Injection
Product Images NDC 16729-243

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topotecan (NDC 16729-243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 2 (Topotecan 1 mg Per mL Carton)

This appears to be a label or instruction sheet for a medication in vial form. It includes information on dilution requirements, intravenous infusion, cautionary notes about cytotoxic agents, and mention of lot and expiration information for the product. The text also references a 2D matrix and measurements for an unvarnished area for pasting.*

FDA Label Image

Image 1 (Topotecan 1 mg Per mL Container Label)

TOPPOLECAN Injection is a cytotoxic agent that requires careful handling and a review of the package insert for administration protocols. The typical dosage is 1mg/mL, and the medication should be stored between 20°C to 25°C while being protected from light. The medication must be diluted before use and should be used within 28 days of opening. This medication is only available through prescription, and it is produced in India by Accord Healthcare.*

FDA Label Image

Image 4 (Topotecan 4 mg Per 4 mL Carton)

Description not available.*

FDA Label Image

Image 3 (Topotecan 4 mg Per 4 mL Container Label)

This is a description for a medication named "Topotecan Injection SRS". The medication comes in a 4mL multiple-dose vial that must be stored at 20°C to 25°C (68°F to 77°F). The medication is a cytotoxic agent and must be used within 28 days after the first use. The vial must be protected from light and retained in the carton. For details on dosage, refer to the insert. The rest of the text contains information unrelated to the medication, and it is not available what it is about.*

FDA Label Image

Figure 10 (Topotecan Graph1)

This is a comparison between Topotecan Injection plus Cisplatin and Cisplatin Monotherapy in a study that lasted for some months. No further information is available from the given text.*

FDA Label Image

Structural Formula (Topotecan Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.